A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer
Authors
Keywords
Metastatic breast cancer, Topoisomerase 1 inhibitors, Treatment, Systematic review
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 138, Issue 2, Pages 347-358
Publisher
Springer Nature
Online
2013-03-19
DOI
10.1007/s10549-013-2476-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 1st International consensus guidelines for advanced breast cancer (ABC 1)
- (2012) F. Cardoso et al. BREAST
- A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
- (2012) G. S. Jameson et al. CLINICAL CANCER RESEARCH
- Clinical development of new formulations of cytotoxics in solid tumors
- (2012) Hatem A. Azim et al. CURRENT OPINION IN ONCOLOGY
- Topoisomerase 1 Inhibitors and Cancer Therapy
- (2012) Julia Moukharskaya et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer
- (2012) Keun Seok Lee et al. INVESTIGATIONAL NEW DRUGS
- EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors
- (2012) Serge A. L. Zander et al. PLoS One
- Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer
- (2011) R. Wendel Naumann et al. DRUGS
- Irinotecan and bevacizumab in recurrent glioblastoma multiforme
- (2011) Jan Nyrop Jakobsen et al. EXPERT OPINION ON PHARMACOTHERAPY
- Oxaliplatin: a review of approved uses
- (2011) Alexander Stein et al. EXPERT OPINION ON PHARMACOTHERAPY
- Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer
- (2011) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
- (2011) Nancy U. Lin et al. JOURNAL OF NEURO-ONCOLOGY
- TOP1gene copy numbers in colorectal cancer samples and cell lines and their association toin vitrodrug sensitivity
- (2011) Maria Unni Rømer et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Other Options in the Treatment of Advanced Breast Cancer
- (2011) Melody A. Cobleigh SEMINARS IN ONCOLOGY
- Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma
- (2010) Vittorio Gebbia et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Treatment of metastatic breast cancer: second line and beyond
- (2010) H. Roche et al. ANNALS OF ONCOLOGY
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
- (2010) Paula M. Fracasso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Topotecan for relapsed small cell lung cancer: A systematic review and economic evaluation
- (2010) Debbie Hartwell et al. CANCER TREATMENT REVIEWS
- N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial
- (2009) W. W. Tan et al. ANNALS OF ONCOLOGY
- Review role of topotecan in gynaecological cancers: Current indications and perspectives
- (2009) Domenica Lorusso et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- 6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)
- (2009) M. Koopman et al. EJC SUPPLEMENTS
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
- (2009) Fatima Cardoso et al. JNCI-Journal of the National Cancer Institute
- Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer
- (2009) Mikihiro Kusama et al. Breast Cancer
- Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC)
- (2008) E. Mrozek et al. ANNALS OF ONCOLOGY
- Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response
- (2008) Stacy Moulder et al. CANCER
- Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors
- (2008) Giovanni Luca Beretta et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment
- (2008) Kathy S. Albain et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
- (2008) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
- (2008) A. M. Brewster et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search